Ebola virus disease in Spain recuperation from her illness. The WHO declared Spain Ebola-free on 2 December, 42 days after Teresa Romero was shown to be free of Ebola on 21 October. In July 2018, a Spanish team from the in Madrid announced the discovery of an antibody and the development of a prototype vaccine against five strains of Ebola, including the most common and deadliest. Ebola virus disease in Spain In 2014, Ebola virus disease in Spain occurred due to two patients with cases of the disease contracted during the Ebola virus epidemic in West Africa; they were medically evacuated. A failure in infection
TKM-Ebola TKM-Ebola TKM-Ebola was an experimental antiviral drug for Ebola disease that was developed by Arbutus Biopharma (formerly Tekmira Pharmaceuticals Corp.) in Vancouver, Canada. The drug candidate was formerly known as Ebola-SNALP. TKM-Ebola is a combination of small interfering RNAs targeting three of the seven proteins in Ebola virus: Zaire Ebola L polymerase, Zaire Ebola membrane-associated protein (VP24), and Zaire Ebola polymerase complex protein (VP35). By down-regulating these three proteins, TKM-Ebola inhibits virus replication and eliminates the infection. The drug was effective in rhesus monkeys infected with Ebola. After the Ebola outbreak in West Africa in 2014, the new variant responsible